Associated Papers
Investigation of Exome-Wide Tumor Heterogeneity on Colorectal Tissue-Based Single Cells.
Szakállas N et al.
International Journal of Molecular Sciences, 2025
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Surveillance of cfDNA Hot Spot Mutations in NSCLC Patients during Disease Progression.
Sestokaite A et al.
International Journal of Molecular Sciences, 2023
Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors-Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
Alen BO et al.
Cancers, 2022
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer.
Stein A et al.
Journal for Immunotherapy of Cancer, 2021
Cell Free Tumoral DNA Versus Paraffin Block Epidermal Growth Factor Receptor Mutation Detection in Patients with Non-Small Cell Lung Cancer.
Mirtavoos-Mahyari H et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2019
Prevalence of EGFR Mutations in Lung Cancer in Uruguayan Population.
Berois N et al.
Journal of Cancer Epidemiology, 2017
Mutation analysis of genes in the EGFR pathway in Head and Neck cancer patients: implications for anti-EGFR treatment response.
Boeckx C et al.
Bmc Research Notes, 2014
Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors.
Gilbert JA et al.
Pancreas, 2013
Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.
Weiss GA et al.
Journal of Gastrointestinal Oncology, 2013
Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
Uribe P et al.
Pathology, Research and Practice, 2011
Lack of EGFR-activating mutations in European patients with triple-negative breast cancer could emphasise geographic and ethnic variations in breast cancer mutation profiles.
Jacot W et al.
Breast Cancer Research : Bcr, 2011
Detection of EGFR and KRAS mutations on trans-thoracic needle aspiration of lung nodules by high resolution melting analysis.
Fassina A et al.
Journal of Clinical Pathology, 2009
A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes.
Heideman DA et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology, 2009
High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies.
Do H et al.
Bmc Cancer, 2008
Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma.
Lee J et al.
Cancer, 2007
Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer.
Tzeng CW et al.
Surgery, 2007
Global profiling of EGFR gene mutation, amplification, regulation and tissue protein expression in unknown primary carcinomas: to target or not to target?
Dova L et al.
Clinical & Experimental Metastasis, 2007
Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.
Conde E et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2006
NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy.
Kauffmann-Guerrero D et al.
Respiration; International Review of Thoracic Diseases, 0